Support and Safety

ESTABLISHED CLINICAL RISK: Knuijver 2022; Hildyard 2016; Henstra 2017; Drew 2010 general cardiology.

Magnesium administration requires the actual concentration, dilution, rate, and repeat plan in the emergency order. Continue ECG and hemodynamic monitoring after conversion; recurrent pause dependent episodes may require rate support. Arrange hospital care early when recurrence or persistent repolarization abnormality exceeds local capability. See the medication reference for the adult example and monitoring requirements.

GENERAL EMERGENCY STANDARD + IBOGAINE CASE EVIDENCE: Hildyard 2016; Henstra 2017; Drew 2010; ESC ventricular arrhythmia guideline 2022.

For bradycardia with poor perfusion, prepare atropine and pacing. If atropine is ineffective, an epinephrine or dopamine infusion or transcutaneous pacing may bridge to definitive care. Check for hypoxia, electrolyte disturbance, coexposures, and long QT with pause triggered ectopy. Avoid treating an isolated rate value without assessing perfusion (Wigginton et al., 2025).

ESTABLISHED CLINICAL RISK: Knuijver 2022; toxicology case literature; general ACLS/cardiology practice.

ESTABLISHED CLINICAL RISK: Edwards 2025; Hildyard 2016; Henstra 2017; general resuscitation standards.

Begin the status epilepticus pathway for a convulsion lasting five minutes or repeated seizures without recovery. IV lorazepam or IM midazolam are established initial options; give the protocol dose promptly with airway equipment ready. Check glucose and correct an identified abnormality. Persistent seizure activity needs an additional treatment pathway and urgent hospital care. Suspected toxicological seizures require cause specific selection; phenytoin is not recommended for drug induced seizures (Glauser et al., 2016; Chen et al., 2016).

EMERGING HUMAN SAFETY EVIDENCE: Hildyard 2016 and adverse event reviews; general seizure care standards.

Dizziness, vestibulocerebellar dysfunction, and movement sensitive nausea are documented parts of the ibogaine experience. Luciano described prominent movement induced vomiting with transient nystagmus, intention tremor, and gait ataxia, while later human cohorts confirm substantial transient cerebellar impairment. Treat unnecessary movement as a symptom trigger when the patient is medically stable, but keep a broad differential for new or persistent vertigo.

Evidence basis: peer reviewed human ibogaine observation (Luciano, 1998), monitored human ataxia data (Knuijver et al., 2022), and general vestibular nausea physiology (Yates et al., 2014). No trial has validated “stay still” as a quantified ibogaine antiemetic intervention, so movement minimization is labeled supportive expert practice.

ESTABLISHED CLINICAL EFFECT IN ONE SMALL COHORT: Knuijver 2022 and 2024; O’Connell 2015.

Patient centered practice: severe ataxia can leave the person mentally present while the body becomes unreliable. Offer direct help with standing, transfers, and toileting, explain what you are doing, and preserve privacy as much as possible. In Knuijver’s cohort, ataxia was universal, worst two to six hours after dosing, and significant enough that nursing assistance was needed for bathroom trips; several participants still had residual findings at 24 hours.

Obtain medical review for repeated vomiting, poor oral intake, or inability to retain fluids. Replace clinically significant losses, recheck potassium and magnesium, and select an antiemetic using the current ECG and medication history. Ondansetron and droperidol add QT concerns; palonosetron and NK1 antagonists offer different QT profiles for clinician consideration. Evidence from other settings supports that comparison, while ibogaine exposure adds patient specific risk. Hypoxia or loss of airway protection requires immediate respiratory support and transfer.

ESTABLISHED COMMON ADVERSE EFFECT; ASPIRATION DOCUMENTED: Mazoyer 2013; O’Connell 2015; toxicology reviews.

Experiential overlay: vomiting can yank a deeply inward person into an urgent physical problem while coordination is already poor. Keep emesis access, positioning, airway observation, privacy, fluid loss assessment, and help with movement ready before the person needs to ask.

EMERGING HUMAN SAFETY EVIDENCE: Ona 2022; poison center cases; general delirium practice.

Differential diagnosis note: vivid visions, symbolic speech, spiritual language, and transient fear can occur within the expected altered state. Delirium is identified through attention, awareness, arousal, fluctuation, neurological findings, oxygenation, withdrawal state, medication exposure, and physiological stability. Let those objective features carry the diagnostic weight.

When a serotonergic combination is possible, examine for clonus, hyperreflexia, rigidity, and temperature rise. That pattern changes the pathway toward toxicology assessment, benzodiazepines when indicated, cooling, and intensive care for severe toxicity. Cyproheptadine is an optional oral adjunct considered alongside supportive treatment (Chiew & Isbister, 2025).

EMERGING CASE BASED EVIDENCE: Marta 2015; Houenou 2011; Ona 2022. Case reports do not establish incidence or blanket contraindications.

Transient persecutory mistrust sits near this differential. Brief mistrust of the room can settle when stimulation drops and trust is restored. Fixed persecutory beliefs, pressured or disorganized speech, grandiosity, persistent inability to sleep, threats, loss of behavioral control, or symptoms that keep intensifying after the acute drug state deserve a higher level of concern. The mania and psychosis literature after ibogaine is small, so trajectory and function are more useful than rushing to a label.

Medication should follow the suspected cause. Withdrawal and serotonin toxicity may call for benzodiazepines; a primary psychiatric syndrome may need a different regimen. Review QT, breathing, blood pressure, recent sedatives, and neurological findings before and after treatment. Escalating sedation requirements or inability to assess safely warrants emergency care.